Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Atea Pharmaceuticals will report Q1 2026 results after the close on May 12, 2026; analysts expect EPS of ($0.60) and revenue of $22.419 million, with the earnings call at 4:30 PM ET.
• The company missed the prior quarter (reported EPS ($0.57) vs. consensus ($0.49)), and analysts forecast about -$2 EPS for both the current and next fiscal years.
• Shares trade near $5.68 with a market cap around $454M and ~86.7% institutional ownership; analyst views are mixed (consensus "Moderate Buy" but a recent Weiss Ratings "sell").

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) is anticipated to issue its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.60) per share and revenue of $22.4190 million for the quarter. Parties may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last released its earnings results on Thursday, March 5th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). On average, analysts expect Atea Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Atea Pharmaceuticals Price Performance

NASDAQ:AVIR traded down $0.03 on Tuesday, reaching $5.68. The stock had a trading volume of 13,182 shares, compared to its average volume of 476,893. The company has a market cap of $454.17 million, a price-to-earnings ratio of -2.94 and a beta of 0.38. The firm's fifty day moving average is $5.52 and its two-hundred day moving average is $4.20. Atea Pharmaceuticals has a 12-month low of $2.45 and a 12-month high of $6.45.

Analyst Ratings Changes

Separately, Weiss Ratings restated a "sell (d-)" rating on shares of Atea Pharmaceuticals in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy".

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of AVIR. Prudential Financial Inc. purchased a new position in shares of Atea Pharmaceuticals during the 2nd quarter worth about $36,000. BNP Paribas Financial Markets lifted its holdings in shares of Atea Pharmaceuticals by 57.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company's stock worth $58,000 after acquiring an additional 7,286 shares during the period. Jump Financial LLC lifted its holdings in shares of Atea Pharmaceuticals by 36.5% during the 4th quarter. Jump Financial LLC now owns 19,113 shares of the company's stock worth $68,000 after acquiring an additional 5,106 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Atea Pharmaceuticals during the 4th quarter worth about $69,000. Finally, Marshall Wace LLP purchased a new position in shares of Atea Pharmaceuticals during the 2nd quarter worth about $90,000. 86.67% of the stock is currently owned by hedge funds and other institutional investors.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company's lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea's pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.